Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-na ïve, HER2-positive advanced gastric cancer

ConclusionsTrastuzumab with SOX had promising activity with well-tolerated toxicities for patients with HER2-positive AGC.Clinical trial registrationUMIN000017602.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research